Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development

Acta Pharmaceutica Sinica B

Mohammad Javad Sanaei¹  Masoud Heshmati²  Zahra Asadzadeh²  Reza Jafari³  Iman Azimi⁴  Seyed Hossein Kiaie⁴  Saleh Hadidi⁵  Behzad Baradaran⁶ 

[1] Nano Drug Delivery Research Center, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran;Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord 8815713471, Iran;Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord 8815713471, Iran;Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5173957616, Iran;School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Hobart 7001, Tasmania, Australia;Solid Tumor Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia 5714783734, Iran;

关键词: Immune checkpoint;    Pancreatic cancer;    Tumor microenvironment;    Immunotherapy;    Clinical development;   

DOI  :  

来源: DOAJ

【 摘 要 】

Immunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or few effective treatment options thus far. In this process, immunosuppression in the tumor microenvironment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosuppression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest studies to clinical applications of ICP-targeted therapy in PCa.

【 授权许可】

Unknown